Breaking News, Trials & Filings

Boehringer’s Survodutide Achieves Primary Endpoint in MASH Trial

Has the potential to become a best-in-class treatment for MASH, a liver disease connected with other cardiovascular, renal, and metabolic conditions.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase II trial. The trial met its primary endpoint with survodutide reaching a biopsy-proven improvement in MASH after 48 weeks, without worsening of fibrosis stages F1, F2 and F3 (mild to moderate or advanced scarring). Survodutide also met all secondary endpoints, in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters